Effect of the Interaction between Obstructive Sleep Apnea and Lipoprotein(a) on Insulin Resistance: A Large-Scale Cross-Sectional Study

Yupu Liu,1,2,3 Juanjuan Zou,1,2,3 Xinyi Li,1,2,3 Xiaolong Zhao,1,2,3 Jianyin Zou,1,2,3 Suru Liu,1,2,3 Lili Meng,1,2,3 Yingjun Qian,1,2,3 Huajun Xu,1,2,3 Hongliang Yi,1,2,3 Jian Guan,1,2,3 and Shankai Yin1,2,3

1Department of Otolaryngology, Therapy Center for Obstructive Sleep Apnea, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 600 Yishan Road, Xuhui District, Shanghai 200233, China
2Otolaryngology Institute of Shanghai Jiao Tong University, China
3Shanghai Key Laboratory of Sleep Disordered Breathing, China

Correspondence should be addressed to Jian Guan; guanjian0606@sina.com and Shankai Yin; yinshankai@china.com

Received 7 November 2018; Revised 11 March 2019; Accepted 19 March 2019; Published 8 April 2019

Both obstructive sleep apnea (OSA) and decreased serum lipoprotein(a) (Lp(a)) concentrations are associated with insulin resistance. However, their interaction effect on insulin resistance has never been investigated. Therefore, we performed a cross-sectional study on OSA-suspected Chinese Han participants. Laboratory-based polysomnographic variables, biochemical indicators, anthropometric measurements, and medical history were collected. Linear regression and binary logistic regression analyses with interaction terms were used to investigate the potential effects of the interaction between the severity of OSA (assessed by the apnea-hypopnea index (AHI)) and Lp(a) concentrations on insulin resistance (assessed by the homeostasis model assessment of insulin resistance (HOMA-IR)), after adjusting for potential confounders including age, gender, body mass index, waist-to-hip circumference ratio, mean arterial pressure, smoking status, drinking status, and lipid profiles. A total of 4,152 participants were enrolled. In the OSA-suspected population, AHI positively correlated with insulin resistance and serum Lp(a) concentrations independently and inversely correlated with insulin resistance. In addition, the interaction analysis showed that the linear association between lgAHI and lgHOMA-IR was much steeper and more significant in subjects with relatively low Lp(a) concentrations, suggesting a significant positive interaction between lgAHI and lgLp(a) concentrations on insulin resistance (assessed by the homeostasis model assessment of insulin resistance (HOMA-IR)), after adjusting for potential confounders including age, gender, body mass index, waist-to-hip circumference ratio, mean arterial pressure, smoking status, drinking status, and lipid profiles. A stronger association between AHI quartiles and the presence of insulin resistance (defined as HOMA-IR > 3) could be observed for participants within lower Lp(a) quartiles. In conclusion, a significant positive interaction was observed between OSA and decreased Lp(a) with respect to insulin resistance. This association might be relevant to the assessment of metabolic or cardiovascular disease risk in OSA patients.

1. Introduction

Obstructive sleep apnea (OSA) is the most common form of sleep-disordered breathing and is characterized by recurrent episodes of complete or partial upper airway obstruction during sleep [1]. These obstructive events lead to multiple adverse physiological changes, including intermittent hypoxia, sleep fragmentation, inflammation, oxidative stress, and increased sympathetic tone. Together, these changes could predispose OSA patients to a higher risk of insulin resistance [2–5], a pathological condition which plays important roles in the pathogenesis of various metabolic and cardiovascular diseases (CVD), including metabolic syndrome, type 2 diabetes, hypertension, atherosclerosis, and stroke [6–8].
Low serum lipoprotein(a) (Lp(a)) concentration is recognized as another risk factor for insulin resistance [9–14]. Lp(a) is a highly atherogenic lipoprotein composed of a low-density lipoprotein- (LDL-) like particle covalently bound to apo(a) [15]. Its serum concentrations have a more than 1,000-fold interindividual range and are primarily genetically determined by the LPA gene without other major anthropometric, dietary, or environmental influences [15–19]. Recently, observational studies demonstrated that decreased Lp(a) is associated with a higher risk of insulin resistance in several populations including diabetic, nondiabetic, hypertensive, and dyslipidemic patients, indicating that low Lp(a) levels may be associated with the development of insulin resistance [9–14, 20].

However, to our knowledge, no prior studies have investigated whether Lp(a) is related to insulin resistance in individuals with suspected OSA. In addition, it is also unknown whether there is any interaction between Lp(a) and OSA with respect to the severity of insulin resistance. These questions are of potential clinical importance as they are relevant to the assessments of metabolic and cardiovascular disease risk in OSA patients. For instance, because Lp(a) is highly atherogenic, it has been recommended that its concentrations should be lowered in individuals with a high risk of CVD [21–23]. However, this treatment may lead to an excessive risk of insulin resistance and subsequent adverse metabolic or cardiovascular consequences in OSA patients [24–26].

Therefore, we set up a cross-sectional study of 5,479 OSA-suspected participants with the aims to (1) investigate the relationships between Lp(a) and insulin resistance in an OSA-suspected population and (2) test for an interaction effect of Lp(a) and OSA on insulin resistance.

2. Methods

2.1. Study Population. Participants were enrolled from the Shanghai Sleep Health Study cohort, which included a total of 5,479 unrelated consecutive suspected OSA subjects who were referred to the Sleep Center of the Affiliated Sixth People’s Hospital, Shanghai Jiao Tong University, from January 2007 to June 2017. Participants were mainly residents of cities in southern China, and all were Han Chinese. Informed consent was obtained in writing from each participant according to the guidance of the National Ethics Regulation Committee of China. This study was approved by the Institutional Ethics Committee of the Sixth Affiliated Hospital of Shanghai Jiao Tong University.

The exclusion criteria were as follows: (1) age less than 18 years; (2) history of OSA diagnosis or treatment; (3) use of lipid-lowering drugs; (4) use of insulin or oral hypoglycemic agents; (5) systemic steroid treatment or hormone-replacement therapy; (6) severe comorbid diseases, such as congestive heart failure, psychiatric disturbances, chronic liver disease, or chronic kidney disease; (7) acute inflammation; (8) recorded total sleep time < 4 h; (9) sleep disorders other than OSA, such as central sleep apnea or narcolepsy; and (10) unavailable clinical data. Finally, 1,327 met the exclusion criteria and were excluded from the study.

2.2. Medical History and Physical Measurements. Before overnight polysomnography (PSG), all participants were asked to complete a uniform questionnaire regarding medical histories, smoking status, and drinking status. Current smoking or drinking was defined as regular consumption of cigarettes or alcohol in the past six months [27]. Height and weight were measured using standard anthropometric methods, with the participants dressed in lightweight clothing and with bare feet. Body mass index (BMI) was calculated as weight divided by height squared (kg/m²). Blood pressure was measured with participants in a seated position after a 5 min rest and recorded as the average value of three sequential measurements at 1 min intervals. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were recorded. Mean arterial pressure (MAP) was calculated as (SBP + 2 * DBP)/3.

2.3. Overnight Polysomnography Parameters. Overnight PSG was conducted in the sleep center of the Shanghai Jiao Tong University Affiliated Sixth People’s Hospital with an Alice 4 system (Philips Respironics Inc., Pittsburgh, PA, USA). Data recorded included electroencephalography, electrooculography, submental electromyogram, oronasal airflow (nasal pressure and thermistor), chest and abdominal movements, electrocardiogram, peripheral SpO₂, and body positions. All recordings were analyzed manually according to standard criteria by the same skilled technician [28]. Apnea was defined as the complete cessation of airflow lasting ≥10 s. Hypopnea was defined as either a decrease of airflow ≥50% for a duration of ≥10 s or a decrease of airflow <50% but accompanied by a decrease in SaO₂ ≥4% or an arousal. The apnea-hypopnea index (AHI) was defined as the total number of apneas and hypopneas per hour during sleep. OSA was diagnosed as AHI ≥5 events per hour.

2.4. Biochemical Indicators. For each participant, a fasting blood sample was drawn from the antecubital vein in the morning after polysomnographic monitoring. Blood samples were assayed by laboratory staff in our hospital unaware of participants’ disease status. Serum Lp(a) concentrations were measured using a high-sensitivity immunoturbidimetric assay which was able to detect Lp(a) concentrations from 0 to 100 mg/dL. Blood samples with Lp(a) > 100 mg/dL were routinely diluted 1:10. The other biochemical indicators (fasting insulin and fasting blood glucose) and lipid profiles (total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A-I (ApoA-I), and apolipoprotein B (ApoB)) were quantified according to manufacturer specifications using a Hitachi H-7600 analyzer.

The severity of insulin resistance was quantified by calculating the homeostasis model assessment of insulin resistance (HOMA-IR, calculated as the product of fasting glucose (mmol/L) and fasting insulin (mU/L) divided by 22.5). Insulin resistance was defined as HOMA-IR > 3.0 [29]. HOMA-IR correlates well with the hyperinsulinemia euglycemic clamp (the gold standard measure of insulin resistance), thus enabling accurate identification of individuals with insulin resistance [30].
Furthermore, the e were examined for linearity before logistic regression. All continuous variables, including Lp(a) quartiles, using the top quartile of Lp(a) or the bottom quartile of AHI as the reference. All continuous variables, including Lp(a) and AHI (as continuous variables) on HOMA-IR was assessed with linear regression analysis by adding an interaction term to the regression model. The multiplicative interaction between quartiles of Lp(a) and AHI with respect to insulin resistance was assessed with logistic regression analysis. Statistical analyses were performed using SPSS v.24.0.0 (IBM Corp., Armonk, NY, USA) and R software package 3.4.1 (http://www.r-project.org/). All P values given are two-sided, with the significance level set to 0.05.

### 3. Results

#### 3.1. Basic Characteristics of Participants

Among the 4,152 included participants, 79.0% were found to have OSA and 21.0% were not, 79.6% were men and 20.4% were women, with a median age of 41.0 years, the median Lp(a) concentration was 7.40 mg/dL, and the median AHI was 27.9 events/h. There were 1,595 participants with insulin resistance, and the prevalence rate was 38.4%.

The general characteristics of all participants, 79.0% were found to have OSA and 21.0% were not, 79.6% were men and 20.4% were women, with a median age of 41.0 years, the median Lp(a) concentration was 7.40 mg/dL, and the median AHI was 27.9 events/h. There were 1,595 participants with insulin resistance, and the prevalence rate was 38.4%.

#### 3.2. Relationship between AHI and Insulin Resistance in an OSA-Suspected Population

The general characteristics of all participants categorized by AHI quartiles are shown in Table 1. Participants in the lowest to highest quartiles of AHI had a median AHI of 2.2, 16.2, 42.5, and 70.3 events/h, respectively. After multiple adjustments, lgAHI was independently and positively associated with lgHOMA-IR (Table 2; \( \beta = 0.070, P < 0.001 \)). The adjusted odds ratios for insulin resistance (%) 169 (16.0%) 334 (32.4%) 424 (41.7%) 668 (63.6%)
resistance across AHI quartiles 2–4 were 1.61, 1.92, and 2.87, respectively, as compared to the lowest AHI quartile (Table 3; P for linear trend < 0.001), indicating an independent, positive relationship between OSA severity and insulin resistance.

### 3.3. Relationship between Lp(a) and Insulin Resistance in an OSA-Suspected Population

The general characteristics of participants according to the quartiles of serum Lp(a) concentrations are summarized in Table 4, and the P value for each relationship was calculated using each quartile of serum Lp(a) concentrations taken as a unit. Participants in the lowest to highest quartiles of Lp(a) had median serum Lp(a) concentrations of 2.50, 5.50, 10.40, and 25.10 mg/dL, respectively. Across the four quartiles, a significant increasing trend was found regarding age and fasting serum concentrations of TC, LDL-C, HDL-C, and ApoB. Meanwhile, a significant decreasing trend was found regarding the percentage of male participants; AHI; BMI; fasting serum concentrations of glucose, insulin, and TG; HOMA-IR; and the percentage of participants with insulin resistance (Table 4). As shown, from the lowest Lp(a) quartile to the highest, a decreasing trend in HOMA-IR (from 2.74 to 2.22, P for linear trend < 0.001) and the presence of insulin resistance (44.4% to 33.0%, P for linear trend < 0.001) was observed.

Linear regression analysis demonstrated that lgLp(a) significantly and inversely correlated with lgHOMA-IR, both in the unadjusted model (Table 2, β = −0.067, P < 0.001) and the multivariable-adjusted model incorporating potential confounders including AHI, age, gender, BMI, waist-to-hip circumference ratio, MAP, current smoking status, current drinking status, TC, TG, HDL-C, LDL-C, ApoA-I, and ApoB.

### Table 2: The association between lgAHI and lgLp(a) with insulin resistance-related traits.

| Dependent | Independent lgAHI | Independent lgLp(a) |
|-----------|-------------------|---------------------|
|           | B     | SE (β) | Beta | P     | B     | SE (β) | Beta | P     |
| Unadjusted |       |       |      |       |       |       |      |       |
| lgHOMA-IR | 0.188 | 0.007 | 0.402 | <0.001 | −0.067 | 0.011 | −0.098 | <0.001 |
| lgFBG     | 0.033 | 0.002 | 0.276 | <0.001 | −0.010 | 0.003 | −0.060 | <0.001 |
| lgFSI     | 0.156 | 0.006 | 0.371 | <0.001 | −0.058 | 0.009 | −0.094 | <0.001 |
| Adjusted  |       |       |      |       |       |       |      |       |
| lgHOMA-IR | 0.070 | 0.007 | 0.150 | <0.001 | −0.034 | 0.009 | −0.050 | <0.001 |
| lgFBG     | 0.012 | 0.002 | 0.103 | <0.001 | −0.007 | 0.003 | −0.044 | 0.004  |
| lgFSI     | 0.058 | 0.006 | 0.139 | <0.001 | −0.026 | 0.008 | −0.044 | <0.001 |

Values were calculated with unadjusted and multivariable-adjusted linear regression analyses. Adjusted variables include Lp(a) or AHI, age, gender, BMI, waist-to-hip circumference ratio, MAP, current smoking status, current drinking status, TC, TG, HDL-C, LDL-C, ApoA-I, and ApoB.

### Table 3: The odds ratios for the presence of insulin resistance across AHI or Lp(a) quartiles.

| AHI quartiles | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | P for linear trend |
|---------------|------------|------------|------------|------------|-------------------|
| n (cases/participants) | 169/1,053  | 334/1,031  | 424/1,017  | 668/1,051  | —                 |
| Unadjusted | 1 | 2.51 (2.03, 3.10) | 3.74 (3.05, 4.61) | 9.12 (7.43, 11.25) | <0.001 |
| Adjusted | 1 | 1.61 (1.27, 2.05) | 1.92 (1.50, 2.46) | 2.87 (2.23, 3.70) | <0.001 |
| Lp(a) quartiles | n (cases/participants) | 456/1,026  | 427/1,062  | 371/1,032  | 341/1,032  | — |
| Unadjusted | 1.62 (1.36, 1.94) | 1.35 (1.14, 1.63) | 1.14 (0.95, 1.36) | 1 | <0.001 |
| Adjusted | 1.40 (1.12, 1.74) | 1.21 (0.98, 1.50) | 1.16 (0.93, 1.43) | 1 | 0.029 |

Odds ratios, 95% confidence intervals, and P values were calculated using logistic regression analyses. Insulin resistance was defined as the HOMA-IR index > 3. AHI quartiles 1–4 correspond to the AHI range of ≤7, 7.1–28, 28.1–57, and >57 events/h, respectively. Lp(a) quartiles 1–4 correspond to the serum Lp(a) concentration range of ≤3.90, 3.91–7.40, 7.41–15.10, and >15.10 mg/dL, respectively. Adjusted variables include Lp(a) or AHI quartiles, age, gender, BMI, waist-to-hip circumference ratio, MAP, current smoking status, current drinking status, TC, TG, HDL-C, LDL-C, ApoA-I, and ApoB.

With the highest quartile of Lp(a) as the reference group, univariate logistic regression showed significantly increased odds ratios for the presence of insulin resistance from Lp(a) quartile 4 to quartile 1 (Table 3, P for linear trend < 0.001). After further adjustment for confounding factors, the trend remained significant (P for linear trend = 0.029), with odds ratios of 1.16 (95% CI: 0.93–1.43) for Lp(a) quartile 3, 1.21 (95% CI: 0.98–1.50) for Lp(a) quartile 2, and 1.40 (95% CI: 1.12–1.74) for Lp(a) quartile 1, suggesting an inverse relationship between the Lp(a) level and insulin resistance in this OSA-suspected population.
We also found a significant positive interaction between Lp(a) and AHI with respect to insulin resistance ($P = 0.044$). More significant trends in the relationship between AHI quartiles and the presence of insulin resistance were observed in subjects within lower Lp(a) quartiles (ORs of insulin resistance across AHI quartiles within Lp(a) quartile 4 were 1.00, 1.53, 1.92, and 2.36; those within Lp(a) quartile 3 were 1.47, 1.85, 1.87, and 2.72; those within Lp(a) quartile 2 were 0.86, 1.82, 2.12, and 3.88; and those within Lp(a) quartile 1 were 1.12, 1.96, 2.71, and 4.01).

### 4. Discussion

With this large-scale cross-sectional study, we first found an independent and inverse relationship between serum Lp(a) levels and the severity of insulin resistance as assessed by HOMA-IR in a population with suspected OSA, after adjustment for multiple potential confounders (Tables 2 and 3). Furthermore, the data revealed that as Lp(a) concentrations decline, the relationship between AHI and insulin resistance is steeper and more significant, suggesting a significant positive interaction between Lp(a) and AHI with respect to insulin resistance (Figures 1 and 2).

Lp(a) is a complex lipoprotein composed of an LDL-like particle covalently bound to apo(a) [15]. Its serum concentrations, which have a more than 1,000-fold interindividual range, are primarily genetically determined by the LPA gene and are thought to remain stable throughout the lifetime without other major influences [15–19]. The exact physiological function of Lp(a) is complex and diverse. First, it is demonstrated to be highly atherogenic; epidemiological and genetic evidence strongly indicates

### Table 4: Characteristics of participants by Lp(a) quartiles.

| mg/dL     | Quartile 1 Lp(a) ≤ 3.90 | Quartile 2 3.90 < Lp(a) ≤ 7.40 | Quartile 3 7.41 < Lp(a) ≤ 15.10 | Quartile 4 Lp(a) > 15.10 | P for trend |
|-----------|-------------------------|---------------------------------|---------------------------------|--------------------------|------------|
| N         | 1,026                   | 1,062                           | 1,032                           | 1,032                    | —          |
| Age (years) | 39.0 (32.0, 49.0)       | 40.0 (33.0, 51.0)               | 42.0 (33.0, 53.0)               | 42.0 (34.0, 53.0)        | <0.001     |
| Male (%)  | 842 (82.1%)             | 854 (80.4%)                     | 819 (79.4%)                     | 790 (76.6%)              | 0.002      |
| BMI (kg/m²) | 26.5 (24.1, 29.4)      | 26.4 (23.9, 29.1)               | 26.2 (24.0, 28.4)               | 25.7 (23.8, 28.4)        | <0.001     |
| Waist-to-hip ratio | 0.95 (0.90, 0.98) | 0.94 (0.90, 0.98)               | 0.94 (0.90, 0.98)               | 0.94 (0.90, 0.98)        | 0.045      |
| SBP (mmHg) | 123 (117, 134)         | 120 (115, 130)                  | 122 (116, 132)                  | 120 (115, 131)           | 0.061      |
| DBP (mmHg) | 80 (73, 86)            | 80 (72, 85)                     | 80 (73, 86)                     | 80 (71, 85)              | 0.043      |
| MAP (mmHg) | 93.3 (88.0, 101.7)     | 93.3 (87.7, 99.8)               | 93.3 (88.0, 101.3)              | 93.3 (86.7, 100.0)       | 0.041      |
| AHI (events/h) | 31.3 (8.4, 62.2)   | 28.4 (7.3, 58.6)                | 26.6 (7.3, 55.9)                | 26.3 (5.9, 53.1)         | <0.001     |
| Lp(a) (mg/dL) | 2.50 (1.70, 3.20)  | 5.50 (4.60, 6.40)               | 10.40 (8.80, 12.40)             | 25.10 (19.50, 36.78)     | <0.001     |
| FBG (mmol/L) | 5.28 (4.90, 5.73)   | 5.24 (4.90, 5.72)               | 5.22 (4.88, 5.68)               | 5.18 (4.87, 5.62)        | <0.001     |
| FSI (IU/mL) | 11.2 (7.4, 17.2)      | 10.7 (7.0, 16.1)                | 10.0 (6.7, 15.3)                | 9.7 (6.6, 14.6)          | <0.001     |
| HOMA-IR | 2.74 (1.65, 4.25)     | 2.53 (1.58, 3.91)               | 2.34 (1.50, 3.80)               | 2.22 (1.49, 3.30)        | <0.001     |
| Insulin resistance (%) | 456 (44.4%)   | 427 (40.2%)                     | 371 (35.9%)                     | 341 (33.0%)              | <0.001     |
| TC (mmol/L) | 4.54 (3.98, 5.18)   | 4.57 (4.00, 5.22)               | 4.66 (4.08, 5.29)               | 4.79 (4.22, 5.34)        | <0.001     |
| TG (mmol/L) | 1.68 (1.09, 2.48)    | 1.57 (1.05, 2.29)               | 1.45 (1.04, 2.00)               | 1.41 (1.01, 2.01)        | <0.001     |
| LDL-C (mmol/L) | 2.79 (2.27, 3.35)  | 2.88 (2.36, 3.40)               | 2.97 (2.47, 3.51)               | 3.06 (2.59, 3.56)        | <0.001     |
| HDL-C (mmol/L) | 1.03 (0.89, 1.18)  | 1.02 (0.90, 1.18)               | 1.04 (0.91, 1.20)               | 1.06 (0.93, 1.23)        | 0.002      |
| ApoA-I (g/L) | 1.07 (0.95, 1.21)   | 1.07 (0.96, 1.20)               | 1.07 (0.96, 1.21)               | 1.09 (0.97, 1.23)        | 0.415      |
| ApoB (g/L) | 0.79 (0.68, 0.93)    | 0.81 ± 0.18                     | 0.83 (0.72, 0.95)               | 0.85 (0.75, 0.98)        | <0.001     |
| Current smoking (%) | 205 (20.2%)   | 205 (19.3%)                     | 228 (22.1%)                     | 176 (17.1%)              | 0.280      |
| Current drinking (%) | 129 (12.6%)    | 147 (13.8%)                     | 148 (13.4%)                     | 128 (12.4%)              | 0.993      |

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; AHI: apnea-hypopnea index; FBG: fast blood glucose; FSI: fast serum insulin; HOMA-IR: homeostasis model assessment of insulin resistance; TC: total cholesterol; TG: total triglyceride; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol. Insulin resistance: HOMA-IR > 3.0.
that elevated Lp(a) is a strong causal risk factor for CVD [21–23]. However, more recent observational studies have demonstrated that decreased Lp(a) is associated with a higher risk of insulin resistance in diabetic, nondiabetic, hypertensive, and dyslipidemic populations. In line with previous studies [9–14, 20], our results demonstrated that Lp(a) was independently and negatively associated with the degree of insulin resistance in an OSA-suspected population.

The mechanism of this inverse association is still unclear. Kamstrup and Nordestgaard suggested that the large Lp(a) isofrom size, which is exhibited in subjects with low Lp(a) levels, may elevate the activity of lipoprotein-associated phospholipase A2 (Lp-PLA2) [20], which stimulates the production of inflammatory cytokines in adipose tissue and leads to insulin resistance [31]. This implies that, in addition to the direct atherogenic role of elevated Lp(a), decreased Lp(a) might in turn contribute to metabolic and cardiovascular risk through insulin resistance [6–8, 26]. However, a “reverse causation” could not be excluded, as several studies have shown that insulin may have a direct effect on serum Lp(a) levels. Haffner et al. found that in patients with type 1 diabetes, insulin therapy was associated with a significant reduction in Lp(a) levels [32]. Additionally, Neelle et al. found that a high level of insulin decreased the synthesis of apo(a), a component of Lp(a) [33]. Conversely, a string of studies conducted in patients with type 2 diabetes opposed a direct effect of insulin on Lp(a) levels because no significant decline in Lp(a) was observed after oral hypoglycemic treatment, despite significant improvement in glucometabolism traits [34–36]. In summary, further studies are needed to clarify the underlying pathophysiological mechanism of the inverse relationship between Lp(a) and insulin resistance, as it may point to new targets for the prevention and treatment of insulin resistance and subsequent metabolic and cardiovascular diseases.

Furthermore, in the present study, we observed a significant positive interaction between increased AHI and decreased Lp(a) with respect to the severity of insulin resistance. As Lp(a) concentrations declined, a steeper and more significant positive relationship between AHI and insulin resistance was observed (Figures 1 and 2). This suggests that increased Lp(a) concentrations, which are primarily genetically determined and remain stable over an individual’s lifetime [15, 16], may biologically enhance the adverse pathophysiological effects of OSA on insulin resistance. Our finding is of clinical importance, as it may be relevant to the assessment of metabolic or cardiovascular disease risk in patients with OSA. For example, it has been recommended that Lp(a) concentrations should be lowered in individuals with a high risk of CVD; however, any treatment that lowers Lp(a) levels to reduce CVD risk may lead to an increased risk of insulin resistance and subsequent adverse metabolic and cardiovascular consequences in patients with untreated OSA [24–26]. Therefore, we suggest that to fully evaluate the risk of metabolic and cardiovascular diseases, the effect of the interaction between Lp(a) and OSA on insulin resistance must be appropriately considered. Besides, extra caution should be applied in interpreting our results, because multivariable linear and logistic analyses both showed that the positive relationship between AHI and HOMA-IR was independent of Lp(a) levels. Therefore, interaction between Lp(a) and AHI observed in this study may potentially benefit risk stratification in patients with suspected OSA; however, it should not influence treatment decision-making.

To the best of our knowledge, this is the first study to assess the association of Lp(a) concentrations and insulin resistance in an OSA-suspected population, as well as to explore the interaction of Lp(a) and AHI on the severity of insulin resistance. Our study has several strengths, including the large sample size, standard PSG recording, and fully adjusted models evaluating interaction effects, which increase the quality of our evidence. Meanwhile, some limitations must be stated. First, because of the cross-sectional study design, causality between AHI, Lp(a), and insulin resistance cannot be inferred. Second, Lp(a) kringle, renal function, inflammation, physical activity, daily alcohol consumption dose, and diet are factors shown to influence both Lp(a) levels and insulin resistance [37–40]. Regretfully, our study was not specifically designed to cover these potential confounders, so their effects could not be accounted for in the analysis. Third, cardiovascular damage or outcomes were not measured. Trials incorporating these outcomes are needed in the future to fully depict the joint effect of OSA, Lp(a), and insulin resistance. Finally, possible discrepancy between statistical effects and biological effects might exist. Further fundamental and intervention studies...
are needed to confirm the biological or clinical impact of our findings.

5. Conclusions

In an OSA-suspected population, serum Lp(a) concentrations inversely and independently correlated with insulin resistance following extensive adjustment. In addition, a significant positive interaction was noted between OSA severity and decreased Lp(a) with respect to the degree of insulin resistance. Proper evaluation of the metabolic and cardiovascular disease risk in OSA patients requires appropriate consideration of these associations. Our results also warrant further investigation into the mechanisms underlying the exacerbation of insulin resistance across OSA severities with declining Lp(a).

Data Availability

The data that support the findings of this study are available from the Department of Otolaryngology, Therapy Center for Obstructive Sleep Apnea, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. But restrictions apply to the availability of these data, which were used under license for the current study, and so they are not publicly available. Data are however available from the authors upon reasonable request and with permission of the Department of Otolaryngology, Therapy Center for Obstructive Sleep Apnea, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Yupu Liu and Juanjuan Zou contributed equally to this work.

Acknowledgments

This study was supported by the following institutions: the National Key R&D Program of China (grant number: 2017YFC0112500); Innovation Program of the Shanghai Municipal Education Commission (grant number: 2017-01-07-00-02-E00047); National Natural Science Foundation of China (grant numbers: 81700896, 81770987, and 81701306); Shanghai Sailing Program (grant number: 17YF1414300); Science and Technology Commission of Shanghai Municipality (grant numbers: 16411950104, 16411950105, and 16411950106); Multi-Center Clinical Research Project from the School of Medicine, Shanghai Jiao Tong University (grant number: DLY201502); and the Shanghai Shen-Kang Hospital Management Center Project (grant number: SHDC12015101).

References

[1] A. Malhotra and D. P. White, “Obstructive sleep apnea,” *The Lancet*, vol. 360, no. 9328, pp. 237–245, 2002.
[2] S. Reutrakul and B. Mokhlesi, “Obstructive sleep apnea and diabetes,” *Chest*, vol. 152, no. 5, pp. 1070–1086, 2017.
[3] L. da Silva Araujo, J. F. R. Fernandes, M. R. S. T. Klein, and A. F. Sanjuliani, “Obstructive sleep apnea is independently associated with inflammation and insulin resistance, but not with blood pressure, plasma catecholamines, and endothelial function in obese subjects,” *Nutrition*, vol. 31, no. 11-12, pp. 1351–1357, 2015.
[4] I. H. Ifitikhar, C. M. Hoyos, C. L. Phillips, and U. J. Magalang, “Meta-analyses of the association of sleep apnea with insulin resistance, and the effects of CPAP on HOMA-IR,
adiponectin, and visceral adipose fat,” *Journal of Clinical Sleep Medicine*, vol. 11, no. 4, pp. 475–485, 2015.

[5] N. M. Punjabi, J. D. Sorkin, L. I. Katzel, A. P. Goldberg, A. R. Schwartz, and P. L. Smith, “Sleep-disordered breathing and insulin resistance in middle-aged and overweight men,” *American Journal of Respiratory and Critical Care Medicine*, vol. 165, no. 5, pp. 677–682, 2002.

[6] B. B. Kahn and J. S. Flier, “Obesity and insulin resistance,” *The Journal of Clinical Investigation*, vol. 106, no. 4, pp. 473–481, 2000.

[7] G. M. Reaven, “Pathophysiology of insulin resistance in human disease,” *Physiological Reviews*, vol. 75, no. 3, pp. 473–486, 1995.

[8] G. Reaven, F. Abbasi, and T. Mclaughlin, “Obesity, insulin resistance, and cardiovascular disease,” *Recent Progress in Hormone Research*, vol. 59, no. 1, pp. 207–223, 2004.

[9] M. Boronat, P. Saavedra, N. Pérez-Martín, M. J. López-Madrazo, C. Rodríguez-Pérez, and F. J. Núñez, “High levels of lipoprotein(a) are associated with a lower prevalence of diabetes with advancing age: results of a cross-sectional epidemiological survey in Gran Canaria, *Spa*, *Cardiovascular Diabetology*, vol. 11, no. 1, p. 81, 2012.

[10] D. L. Rainwater and S. M. Haffner, “Insulin and 2-hour glucose levels are inversely related to LPA concentrations controlled for LPA genotype,” *Atherosclerosis, Thrombosis, and Vascular Biology*, vol. 18, no. 8, pp. 1335–1341, 1998.

[11] M. Sidhu, D. Crook, I. F. Godland, C. Walton, V. Wynn, and M. F. Oliver, “Inverse relationship between serum Lp(a) levels and first-phase insulin secretion,” *Diabetes*, vol. 41, no. 10, pp. 1341–1345, 1992.

[12] L. Marzano, G. L. Colussi, M. del Torre, L. A. Sechi, and C. Catena, “Relationships of plasma lipoprotein(a) levels with insulin resistance in hypertensive patients,” *Metabolism*, vol. 63, no. 11, pp. 1439–1446, 2014.

[13] H. Vaverkova, D. Karasek, M. Halenka, L. Cibičková, and V. Kubíčková, “Inverse association of lipoprotein (a) with markers of insulin resistance in dyslipidemic subjects,” *Physiological Research*, vol. 66, Supplement 1, pp. S113–s120, 2017.

[14] L. Ding, A. Song, M. Dai et al., “Serum lipoprotein (a) concentrations are inversely associated with 2T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population,” *Journal of Lipid Research*, vol. 56, no. 4, pp. 920–926, 2015.

[15] S. Tsimikas, “The re-emergence of lipoprotein(a) in a broader clinical arena,” *Progress in Cardiovascular Diseases*, vol. 59, no. 2, pp. 135–144, 2016.

[16] F. Kronenberg, “Human genetics and the causal role of lipoprotein(a) for various diseases,” *Cardiovascular Drugs and Therapy*, vol. 30, no. 1, pp. 87–100, 2016.

[17] B. Enkhmaa, E. Anuurad, and L. Berglund, “Lipoprotein (a): impact by ethnicity and environmental and medical conditions,” *Journal of Lipid Research*, vol. 57, no. 7, pp. 1111–1125, 2016.

[18] A. Langsted, P. R. Kamstrup, and B. G. Nordestgaard, “Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk,” *Atherosclerosis*, vol. 234, no. 1, pp. 95–101, 2014.

[19] M. Afshar and G. Thanassoulis, “Lipoprotein(a): new insights from modern genomics,” *Current Opinion in Lipidology*, vol. 28, no. 2, pp. 170–176, 2017.

[20] P. R. Kamstrup and B. G. Nordestgaard, “Lipoprotein(a) concentrations, isof orm size, and risk of type 2 diabetes: a Mendelian randomisation study,” *The Lancet Diabetes & Endocrinology*, vol. 1, no. 3, pp. 220–227, 2013.

[21] F. Fogacci, A. F. G. Cicero, S. D’Addato et al., “Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study,” *European Journal of Internal Medicine*, vol. 37, pp. 49–55, 2017.

[22] B. G. Nordestgaard and A. Langsted, “Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology,” *Journal of Lipid Research*, vol. 57, no. 11, pp. 1953–1975, 2016.

[23] P. R. Kamstrup, A. Tybjærg-Hansen, R. Steffensen, and B. G. Nordestgaard, “Genetically elevated lipoprotein(a) and increased risk of myocardial infarction,” *JAMA*, vol. 301, no. 22, pp. 2331–2339, 2009.

[24] S. M. Grundy, I. J. Benjamin, G. L. Burke, and B. G. Nordestgaard, “Genetically elevated lipoprotein(a) and increased risk of myocardial infarction,” *JAMA*, vol. 301, no. 22, pp. 2331–2339, 2009.

[25] H. N. Ginsberg, “Insulin resistance and cardiovascular disease,” *The Journal of Clinical Investigation*, vol. 106, no. 4, pp. 453–458, 2000.

[26] J. Guan, H. Yi, J. Zou et al., “Distinct severity stages of obstructive sleep apnoea are correlated with unique dyslipidaemia: large-scale observational study,” *Thorax*, vol. 71, no. 4, pp. 347–355, 2016.

[27] C. Iber, S. Ancoli-Israel, A. Chesson, and S. F Quan, *The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications*, American Academy of Sleep Medicine, Westchester, IL, USA, 2007.

[28] J. Yin, M. Li, L. Xu et al., “Insulin resistance determined by homeostasis model assessment (HOMA) and associations with metabolic syndrome among Chinese children and teenagers,” *Diabetes & Metabolic Syndrome*, vol. 5, no. 1, p. 71, 2013.

[29] T. M. Wallace, J. C. Levy, and D. R. Matthews, “Use and abuse of HOMA modeling,” *Diabetes Care*, vol. 27, no. 6, pp. 1487–1495, 2004.

[30] T. L. Nelson, M. L. Biggs, J. R. Kizer et al., “Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 97, no. 5, pp. 1695–1701, 2012.

[31] S. M. Haffner, K. R. Tuttle, and D. L. Rainwater, “Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects,” *Diabetes Care*, vol. 14, no. 4, pp. 302–307, 1991.

[32] D. M. Neele, E. C. de Wit, and H. M. Princen, “Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes,” *Diabetologia*, vol. 42, no. 1, pp. 41–44, 1999.

[33] G. Derosa, A. V. Gaddi, L. Ciccarelli et al., “Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-
blind clinical trial,” *Journal of International Medical Research*, vol. 33, no. 3, pp. 284–294, 2005.

[35] S. S. Habib, M. Aslam, A. K. Naveed, and M. S. Razi, “Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy,” *Saudi Medical Journal*, vol. 27, no. 2, pp. 174–180, 2006.

[36] V. A. Fonseca, P. Theuma, S. Mudaliar, C. A. Leissinger, S. Clejan, and R. R. Henry, “Diabetes treatments have differential effects on nontraditional cardiovascular risk factors,” *Journal of Diabetes and its Complications*, vol. 20, no. 1, pp. 14–20, 2006.

[37] F. Fogacci, A. F. G. Cicero, S. D’Addato et al., “Effect of spontaneous changes in dietary components and lipoprotein(a) levels: data from the Brisighella Heart Study,” *Atherosclerosis*, vol. 262, pp. 202–204, 2017.

[38] A. Tolbus, M. B. Mortensen, S. F. Nielsen, P. R. Kamstrup, S. E. Bojesen, and B. G. Nordestgaard, “Kringle IV type 2, not low lipoprotein(a), as a cause of diabetes: a novel genetic approach using SNPs associated selectively with lipoprotein(a) concentrations or with kringle IV type 2 repeats,” *Clinical Chemistry*, vol. 63, no. 12, pp. 1866–1876, 2017.

[39] L. A. Sechi, L. Zingaro, S. De Carli et al., “Increased serum lipoprotein(a) levels in patients with early renal failure,” *Annals of Internal Medicine*, vol. 129, no. 6, pp. 457–461, 1998.

[40] C. Catena, M. Novello, L. Dotto, S. de Marchi, and L. A. Sechi, “Serum lipoprotein(a) concentrations and alcohol consumption in hypertension: possible relevance for cardiovascular damage,” *Journal of Hypertension*, vol. 21, no. 2, pp. 281–288, 2003.